After sliding downwards for most of the year and dropping to a new 52-week low of $0.10 on December 9 the stock of BrainStormCell Therapeutics Inc. (OTCBB:BCLI) is finally showing signs of recovery. During yesterday’s session the ticker surged by 21% and returned to price ranges above 20 cents per share after finishing the day at $0.219.
Interest in the stock also boomed with a total of 1.8 million shares traded throughout the day, a number that is 9 times higher the previous session. The company is starting the new 2014 with a strong chart performance forming a steep positive trend. For the last 5 session the stock has closed in the red only once and as a result nearly 7 cents were added to its value.
As their name shows
BCLI are a biotechnology company that operates in the field of adult stem cell therapies. They are focusing on bone marrow cells that can be used for the treatment of neurodegenerative diseases and more specifically amyotrophic lateral sclerosis (ALS). Unlike many of the other pennystocks that are trying to develop new treatments
BCLI have been able to make steady progress with their research.
The company has an ongoing Phase IIa clinical trial and although no final results have been announced on December 10 they released a PR describing the data as “impressively positive”. Their product NurOwn is going to be featured in an article published in “Muscle & Nerve”. The focus will be on a case report on an individual patient who showed significant improvement after treatment with
BCLI‘s cell therapy. But they are not content with the current scope of their trials and a new Phase 2 study should begin in the US sometime during the first quarter of 2014. In July 2013 they also received the Orphan Drug Designation for NurOwn from the EU authorities.
BCLI managed to further inspire some confidence among their shareholders after they received a $800 thousand non-dilutive funding from Israel’s Office of the Chief Scientist. The boost to their financials was much needed as the cash reserves of the company were still quite low despite the private offering of stock they did in August.
Investors should still keep in mind that
BCLI are not generating any revenues and that is unlikely to change any time soon. They
project having a completed product no early than 2017 and that is only if all the trials are completed successfully. For now their financials are stable enough, at least they were at the end of September, but the company will have to look for new sources of funds during 2014.
Yesterday the stock of Tiger Oil and Energy, Inc. (OTCMKTS:TGRO) crashed hard cutting half a dollar from its value and dropping 42% down to close at $0.68. The $2.5 million pump that pushed the company to the disproportionate heights of $1.50 might be over as StockTips have been silent for the last 5 days. If that is truly the case TGRO might slide even further down towards its pre-pump prices of 20 cents per share.
